Year In Review 2020
The Surfers and guests discuss key lessons learned in 2020 about Drugs and Diagnostics, and Patient Treatment and Perspectives.
Vlad Ratziu discusses a “boiling hot” field of emerging NASH drugs and “particularly rich” data coming from no-invasive diagnostic testing
43.2 2020 Year In Review: Emergence of Non-Invasive Tests and Testing Strategies in Fatty Liver Disease
Mazen Noureddin describes a year in which biopsy’s shortcomings are revealed at the same time as non-invasive testing becomes better and produces more robust data
43.3 2020 Year in Review: Progress in developing clinical endpoints necessary to support drug approvals
Stephen Harrison summarizes a year of progress in improving the tests and analyses used to derive clinical endpoints necessary to initial drug approvals
Roger Green discusses why despite widespread concerns, FDA’s Complete Response Letter to Intercept did not cripple progress in NASH drug development.
44.1 – 2020 Year in Review with Ian Rowe: Simplifying NASH Diagnostics Saves Money, Improves Satisfaction
Ian Rowe discusses how streamlined use of ELF, FIB-4 and FibroScan improves cost effectiveness and patient satisfaction associated with NASH screening
Joern Schattenberg discusses the public health implications of German newspapers beginning to discuss Fatty Liver Disease
Louise Campbell questions the implication of APASL and ALEH endorsing “MAFLD” as Fatty Liver Disease nomenclature and Stephen Harrison discusses behind-the-scenes activities to resolve this issue
Wayne Eskridge describes how hope fell and then rose as patients did not receive the drug approval they expected but then learned about exciting paths for new agents and non-invasive testing